OP04 Safety and efficacy of the terminal complement inhibitor eculizumab in patients with paroxysmal nocturnal hemoglobinuria: Shepherd Phase III clinical study results

Authors :: C. DeCastro
Jaroslaw P. Maciejewski
Petra Muus
H.A. Kroon
L. Coyle
C.L. Fu
Bruno Rotoli
Peter Hillmen
Jörg Schubert
H. Schrezenmeier
Neal S. Young
Lucio Luzzatto
R.P. Rother
Alvaro Urbano-Ispizua
Source :: Leukemia Research. 31:S32-S33
Publication Year :: 2007
Publisher :: Elsevier BV, 2007.

Subjects :: Cancer Research
medicine.medical_specialty
business.industry
Hematology
Eculizumab
medicine.disease
Gastroenterology
Clinical study
Complement inhibitor
Oncology
Internal medicine
medicine
Paroxysmal nocturnal hemoglobinuria
In patient
business
medicine.drug

Tools